Review





Similar Products

pacap antagonist pacap 1 27  (MedChemExpress)
93
MedChemExpress pacap antagonist pacap 1 27
Pacap Antagonist Pacap 1 27, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pacap+1+27/pm40713003-60-11-19?v=MedChemExpress
Average 93 stars, based on 1 article reviews
pacap antagonist pacap 1 27 - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
pituitary adenylate cyclase activating peptide 1 27  (Tocris)
92
Tocris pituitary adenylate cyclase activating peptide 1 27
Pituitary Adenylate Cyclase Activating Peptide 1 27, supplied by Tocris, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pacap+1+27/pmc11492034-40-0-8?v=Tocris
Average 92 stars, based on 1 article reviews
pituitary adenylate cyclase activating peptide 1 27 - by Bioz Stars, 2026-07
92/100 stars
  Buy from Supplier
pacap 1 27  (Tocris)
92
Tocris pacap 1 27
Pacap 1 27, supplied by Tocris, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pacap+1+27/pmc11205257-414-45-52?v=Tocris
Average 92 stars, based on 1 article reviews
pacap 1 27 - by Bioz Stars, 2026-07
92/100 stars
  Buy from Supplier
pacap 1 27  (MedChemExpress)
93
MedChemExpress pacap 1 27
Pacap 1 27, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pacap+1+27/pmc11205257-414-45-46?v=MedChemExpress
Average 93 stars, based on 1 article reviews
pacap 1 27 - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
pacap  (MedChemExpress)
92
MedChemExpress pacap
Pacap, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pacap+1+27/pm38418876-592-29-33?v=MedChemExpress
Average 92 stars, based on 1 article reviews
pacap - by Bioz Stars, 2026-07
92/100 stars
  Buy from Supplier
pacap1 27  (R&D Systems)
93
R&D Systems pacap1 27
Pacap1 27, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pacap+1+27/us11845782-340-94-98?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
pacap1 27 - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
pituitary adenylate cyclase-activating peptide (pacap) amino acids 1–27  (Bachem)
90
Bachem pituitary adenylate cyclase-activating peptide (pacap) amino acids 1–27
Polarized PACAP-treated MSC maintain mesenchymal phenotype. ( A ). Immunophenotyping of PACAP-treated MSC in flow cytometry presents positive expression of the mesenchymal markers CD106 (>50%), CD29 (>80%), CD44 (>70%), CD73 (>60%) and sca-1 (>40%) but negative expression of the hematopoietic markers CD45 (<8%), and CD11b (<5%). Graphs represent flow cytometry histograms for the expression of the different markers. The negative control histogram is presented with the blue filled histogram. ( B ). Both naïve (N = 4) and PACAP-treated MSC (N = 3) expressed detectable levels of VPAC2 receptor mRNA, as detected in real-time PCR. Since the activation of Toll-like receptor 3 (TLR3) is an established marker of the MSC anti-inflammatory phenotype (MSC2) , we administered pituitary <t>adenylate</t> cyclase-activating peptide (PACAP), a neuropeptide with anti-inflammatory properties that is known to upregulate TLR3 and vice versa with TLR4, at 20 nM for 4 days to establish the anti-inflammatory MCS phenotype (MSC2). PACAP treatment of MSC in vitro (pMSC, N = 5) did not increase significantly the expression of TLR3 ( C ) or TLR4 ( D ) but increased the TLR3/TLR4 gene expression ratio ( E ) compared with naïve MSC (N = 4), as detected in real-time PCR. All graphs present mean ± SE. * p < 0.05, Student t -test. ns = non-significant.
Pituitary Adenylate Cyclase Activating Peptide (Pacap) Amino Acids 1–27, supplied by Bachem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pacap+1+27/pmc10003244-114-0-11?v=Bachem
Average 90 stars, based on 1 article reviews
pituitary adenylate cyclase-activating peptide (pacap) amino acids 1–27 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
hy p1023 pacap 1 27 medchemexpress  (MedChemExpress)
93
MedChemExpress hy p1023 pacap 1 27 medchemexpress
Polarized PACAP-treated MSC maintain mesenchymal phenotype. ( A ). Immunophenotyping of PACAP-treated MSC in flow cytometry presents positive expression of the mesenchymal markers CD106 (>50%), CD29 (>80%), CD44 (>70%), CD73 (>60%) and sca-1 (>40%) but negative expression of the hematopoietic markers CD45 (<8%), and CD11b (<5%). Graphs represent flow cytometry histograms for the expression of the different markers. The negative control histogram is presented with the blue filled histogram. ( B ). Both naïve (N = 4) and PACAP-treated MSC (N = 3) expressed detectable levels of VPAC2 receptor mRNA, as detected in real-time PCR. Since the activation of Toll-like receptor 3 (TLR3) is an established marker of the MSC anti-inflammatory phenotype (MSC2) , we administered pituitary <t>adenylate</t> cyclase-activating peptide (PACAP), a neuropeptide with anti-inflammatory properties that is known to upregulate TLR3 and vice versa with TLR4, at 20 nM for 4 days to establish the anti-inflammatory MCS phenotype (MSC2). PACAP treatment of MSC in vitro (pMSC, N = 5) did not increase significantly the expression of TLR3 ( C ) or TLR4 ( D ) but increased the TLR3/TLR4 gene expression ratio ( E ) compared with naïve MSC (N = 4), as detected in real-time PCR. All graphs present mean ± SE. * p < 0.05, Student t -test. ns = non-significant.
Hy P1023 Pacap 1 27 Medchemexpress, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pacap+1+27/pm36395769-222-198-201?v=MedChemExpress
Average 93 stars, based on 1 article reviews
hy p1023 pacap 1 27 medchemexpress - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

Image Search Results


Polarized PACAP-treated MSC maintain mesenchymal phenotype. ( A ). Immunophenotyping of PACAP-treated MSC in flow cytometry presents positive expression of the mesenchymal markers CD106 (>50%), CD29 (>80%), CD44 (>70%), CD73 (>60%) and sca-1 (>40%) but negative expression of the hematopoietic markers CD45 (<8%), and CD11b (<5%). Graphs represent flow cytometry histograms for the expression of the different markers. The negative control histogram is presented with the blue filled histogram. ( B ). Both naïve (N = 4) and PACAP-treated MSC (N = 3) expressed detectable levels of VPAC2 receptor mRNA, as detected in real-time PCR. Since the activation of Toll-like receptor 3 (TLR3) is an established marker of the MSC anti-inflammatory phenotype (MSC2) , we administered pituitary adenylate cyclase-activating peptide (PACAP), a neuropeptide with anti-inflammatory properties that is known to upregulate TLR3 and vice versa with TLR4, at 20 nM for 4 days to establish the anti-inflammatory MCS phenotype (MSC2). PACAP treatment of MSC in vitro (pMSC, N = 5) did not increase significantly the expression of TLR3 ( C ) or TLR4 ( D ) but increased the TLR3/TLR4 gene expression ratio ( E ) compared with naïve MSC (N = 4), as detected in real-time PCR. All graphs present mean ± SE. * p < 0.05, Student t -test. ns = non-significant.

Journal: International Journal of Molecular Sciences

Article Title: Polarized Anti-Inflammatory Mesenchymal Stem Cells Increase Hippocampal Neurogenesis and Improve Cognitive Function in Aged Mice

doi: 10.3390/ijms24054490

Figure Lengend Snippet: Polarized PACAP-treated MSC maintain mesenchymal phenotype. ( A ). Immunophenotyping of PACAP-treated MSC in flow cytometry presents positive expression of the mesenchymal markers CD106 (>50%), CD29 (>80%), CD44 (>70%), CD73 (>60%) and sca-1 (>40%) but negative expression of the hematopoietic markers CD45 (<8%), and CD11b (<5%). Graphs represent flow cytometry histograms for the expression of the different markers. The negative control histogram is presented with the blue filled histogram. ( B ). Both naïve (N = 4) and PACAP-treated MSC (N = 3) expressed detectable levels of VPAC2 receptor mRNA, as detected in real-time PCR. Since the activation of Toll-like receptor 3 (TLR3) is an established marker of the MSC anti-inflammatory phenotype (MSC2) , we administered pituitary adenylate cyclase-activating peptide (PACAP), a neuropeptide with anti-inflammatory properties that is known to upregulate TLR3 and vice versa with TLR4, at 20 nM for 4 days to establish the anti-inflammatory MCS phenotype (MSC2). PACAP treatment of MSC in vitro (pMSC, N = 5) did not increase significantly the expression of TLR3 ( C ) or TLR4 ( D ) but increased the TLR3/TLR4 gene expression ratio ( E ) compared with naïve MSC (N = 4), as detected in real-time PCR. All graphs present mean ± SE. * p < 0.05, Student t -test. ns = non-significant.

Article Snippet: Pituitary adenylate cyclase-activating peptide (PACAP) amino acids 1–27 was purchased from Bachem AG (Switzerland) cat. No. 127317-03-7.

Techniques: Flow Cytometry, Expressing, Negative Control, Real-time Polymerase Chain Reaction, Activation Assay, Marker, In Vitro, Gene Expression